





































































Quantitative sensory tests fairly reflect immediate effects of
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h i g h l i g h t s
• Oxycodone had a significant analgesic effect on low-back pain compared to placebo.
• Oxycodone had significant anti-nociceptive effects on almost all QST modalities.
• Anti-nociceptive effects assessed by QST fairly reflect efficacy of oxycodone.
• QST may be more useful to identify non-responders rather than potential responders.
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a b s t r a c t
Introduction: Quantitative sensory tests (QST) can be used for profiling anti-nociceptive effects of anal-
gesics. However, anti-nociceptive effects detected by QST are not necessarily associated with analgesic
effects in pain patients. As part of a large investigation on low back pain, this paper describes the imme-
diate analgesic and anti-nociceptive effects of oxycodone in chronic low-back pain and ranks different
QST according to their ability to reflect this effect. The results are expected to support the selection of
QST for future studies on potential novel opioid agonists in human pain.
Methods: In this randomized, placebo-controlled and double-blinded cross-over study, 50 patients with
chronic low-back pain received a single oral dose of oxycodone 15 mg or active placebo, and underwent
multiple QST testing. The intensity of low-back pain was recorded during 2 h. The areas under the ROC
curves and 95% confidence intervals were determined, whereby responder status (≥30% pain reduction)
was set as reference variable and changes in QST from baseline were set as classifiers.
Results: Significant analgesic effect on low-back pain as well as anti-nociceptive effects for almost all
QST parameters were observed. The QST with the highest area under the curve were heat pain detection
threshold (0.65, 95%-CI 0.46 to 0.83), single-stimulus electrical pain threshold (0.64, 95%-CI 0.47 to 0.80)
and pressure pain detection threshold (0.63, 95%-CI 0.48 to 0.79).
Conclusions: The results suggest that anti-nociceptive effects assessed by QST fairly reflect clinical effi-
cacy of oxycodone on low-back pain. Pressure pain detection threshold, heat pain detection threshold
and single-stimulus electrical pain threshold may be more suitable to sort out potential non-responders
rather than identifying potential responders to opioid medication. Future pre-clinical human research
may consider these results when investigating the analgesic effect of opioid agonists by means of QST.
∗ Corresponding author at: University Department of Anesthesiology and Pain Therapy, Inselspital, CH-3010 Bern, Switzerland.































































































































































































Opioid prescription for chronic pain has considerably increased
n the past years, particularly for chronic low-back pain [1].
owever, long-term use of opioids for non-cancer conditions is
ontroversial because of numerous side effects such as develop-
ent of tolerance, respiratory depression, constipation or drug
isuse. A recent systematic review found opioids to be better than
lacebo, but not necessarily better than non-opioid analgesics for
hronic low-back pain [2].
Most available studies that have examined the short-term
ffects of opioids did so by means of quantitative sensory tests (QST)
n healthy volunteers [3–6]. However, a significant anti-nociceptive
ffect detected by QST in pain-free volunteers does not necessarily
mply that the drug exerts a clinically meaningful analgesic effect
n pain patients. Given the broad spectrum of QST modalities, it
ould be of relevance to know which QST parameter best reflects
he clinical effect of a drug in a given patient population.
The present study is part of a larger project that investigated the
bility of QST to predict the efficacy of several drugs in chronic low-
ack pain. This sub-study describes the immediate analgesic effect
f oxycodone on chronic low-back pain and its anti-nociceptive
ffects as assessed by QST. The different QST are ranked according
o their ability to reflect these effects. The results are expected to
upport the selection of QST for future studies on potential novel
pioid agonists in human pain.
. Methods
This was a randomized, double-blinded and placebo-controlled
tudy at the University Department of Anesthesiology and Pain
edicine, Inselspital Bern, Switzerland. It was registered with clin-
caltrials.gov (NCT01179828) and approved by the local ethics
ommittee (KEK 213-09). The detailed study protocol [7] and
esults from another substudy [8] have been published. All par-
icipants gave written informed consent prior to enrolment.
.1. Patients
Consecutive patients aged 18–80 years with chronic low-back
ain of at least 3 months duration were eligible. Pain intensity at
he moment of testing had to be ≥3/10 on the numerical rating scale
NRS, 0 = no pain and 10 = worst pain imaginable). Exclusion criteria
ere: suspected radicular pain (as defined by leg pain associated
ith an MRI finding of a herniated disc or spinal stenosis), signs
r suspicion of neurological dysfunction at the tested sites, preg-
ancy (as assessed by pregnancy test), breast feeding, treatment
ith an antidepressant, opioid or anticonvulsant, intake of cen-
rally active substances (including drug or alcohol abuse), allergy
r pharmacological contraindications to the tested drugs, systemic
nflammatory or rheumatologic disease, and major depression
Beck Depression Inventory short form score > 9). Analgesic med-
cation was stopped one week before the first experiment. Only
cetaminophen or ibuprofen were allowed as rescue medication
ntil 24 h before the experiment.
.2. Medication and measurements
In this cross-over study, oxycodone 15 mg and tolterodine
mg (active placebo) were administered in a randomized, double-
linded fashion, after 6 h of fasting and with a minimal wash-out
Published in final edited form as: Scand J Pain. ime of 1 week between experiments. Tolterodine was chosen as an
ctive placebo because it is a centrally active anti-cholinergic drug
hat mimics some of the side-effects of oxycodone (e.g. drowsi-
ess, light sedation), but is devoid of any analgesic effect. Each theverum and the placebo pills were concealed by the hospital phar-
macy using identical-looking red gelatin capsules and packed in
semi-opaque plastic flasks labelled with subject number, lot num-
ber and expiry date. Neither the subject nor the investigators were
aware which flask contained which substance. Randomization was
performed by the pharmacist using a computer-generated random
list.
2.3. Quantitative sensory testing
Quantitative sensory testing (QST) was performed at the leg and
arm of the more painful body side (or randomly selected side in case
of bilateral/midline pain). Pressure pain detection and tolerance
thresholds (PPDT and PPTT) were measured at the second toe using
an electronic algometer (Somedic AB, Horby, Sweden) with a probe
surface of 1 cm2. Pressure was increased at a rate of 30 kPa/s until
the sensation became painful (PPDT) or intolerable (PPTT).
Electrical single-stimulation pain threshold (ESPT) and electrical
repeated-stimulation pain threshold (ERPT with 5 stimuli at 2 Hz
inducing temporal summation) were measured using a constant
current stimulator (Digitimer Ltd, Welwyn Garden City, UK) and
two surface electrodes attached below the lateral malleolus. Bursts
of five 1 ms square wave impulses within 25 ms (perceived as one
single stimulus) were delivered with current intensity increasing
by 0.5 mA until the sensation became painful (ESPT). For ERPT, the
stimuli were repeated five times at a frequency of 2 Hz. Current
intensity of all 5 stimuli was increased in steps of 0.5 mA until
the last 2–3 stimuli were perceived as painful, indicating temporal
summation threshold.
Heat pain detection and tolerance thresholds (HPDT and HPTT)
and cold pain detection threshold (CPDT) were measured at the
leg (L5-dermatome) and at the forearm (C6-dermatome) using a
thermode (TSA II, Medoc, Ramat Yishai, Israel). All measurements
started at 30.0 ◦C, the rate of temperature change was 1 ◦C/s. Sub-
jects stopped the measurements by pressing a button when the
warm sensation turned to pain (HPDT) or when the pain became
intolerable (HPTT) or when the cold sensation started to become
painful (CPDT). In any case, the measurements were stopped at a
temperature of 50.5 ◦C for HPTT or 0 ◦C for CPDT, respectively. CPDT
was dichotomized into patients reaching 0 ◦C without pain (“CPDT
at limit”) and patients who reported pain above 0 ◦C (“CPDT not at
limit”).
Conditioned pain modulation (CPM) was assessed using the cold
pressor test as conditioning stimulus. Electrical train-of-five stim-
ulation was delivered at an intensity 1.2 times stronger than the
previously determined ERPT. This was used as test stimulus and
its painfulness was rated by the subjects on a 0–10 NRS. After
this rating, subjects immersed their contralateral hand into an ice-
saturated water bath (1.5 ± 1 ◦C). Once the cold pain reached an
intensity of 7 on the 0–10 NRS, the test stimulus was repeated at
the same current intensity. Again, a pain rating of that test stimulus
was obtained. The time until cold pain reached 7/10 was recorded.
A decrease in pain rating of the test stimulus was considered a
measure of CPM.
The normative values of all mentioned QST (except CPM) have
been determined in a large sample of 300 healthy volunteers [9] and
– with exception of CPDT – have also been shown to have acceptable
test-retest reliability [10].
2.4. Outcome measures
Low-back pain intensity 2 h after drug intake was the primary
 Oct;17:107-115. doi: 10.1016/j.sjpain.2017.07.004outcome measure. NRS scores for pain in the supine and sitting
position were recorded at baseline and in intervals of 30 min for up
to 2 h after drug intake. Drug responders were defined as patients




























































Number of patients 50
Age 55.0 ± 15.2
Sex (female) 26 (52%)
BMI (kg/m2) 26.5 ± 4.3
Pain duration (years) 12.3 ± 11.1
Surgery due to pain (yes) 10 (20%)
Average NRS 4.9 ± 1.4
Impairment of daily life 2.4 ± 1.2
Catastrophizing score 1.6 ± 1.3
Beck Depression Index 2.2 ± 2.4
Descriptive variables and characteristics of the 50 patients included. BMI = body
mass index, NRS = pain intensity on numeric rating scale (0 = no pain, 10 = worst
pain imaginable). Data are presented as mean ± SD or n (%).
Table 2
Baseline quantitative sensory tests.
Verum session Placebo session
PPDT (kPa) 298 (120) 311 (116)
PPTT (kPa) 465 (151) 480 (140)
ESPT (mA) 6.4 (3.4) 7.0 (3.7)
ERPT (mA) 5.4 (2.8) 5.7 (3.1)
Iwsec (s) 23 (30) 23 (29)
HPDT arm (◦C) 43.6 (4.7) 45.1 (4.1)
HPDT leg (◦C) 46.6 (3.1) 47.0 (3.3)
HPTT arm (◦C) 48.8 (2.2) 49.1 (2.01)
HPTT leg (◦C) 49.6 (1.3) 49.7 (1.4)
CPDT arm (◦C) 11.9 (11.3) 11.9 (10.6)
CPDT leg (◦C) 8.0 (10.8) 8.4 (10.5)
Baseline values of quantitative sensory tests for both verum and placebo session.
Values are presented as mean (SD). PPDT and PPTT = pressure pain detection and
tolerance thresholds, ESPT and ERPT = electric single and repeated stimulus pain
7 Oct;17:107-115. doi: 10.1016/j.sjpain.2017.07.004mpression of change scale (PGIC) was assessed on a 7 point scale
anging from “1 = very much improved” over “4 = no change” to
7 = very much worse”, in intervals of 30 min, starting 30 min after
rug administration.
Age, sex, body mass index (BMI), pain duration in years, history
f surgery due to the painful condition, average pain intensity dur-
ng the last 24 h on a 0–10 NRS, pain-related life interference from
he multidimensional pain inventory (MPI), catastrophizing scale
nd Beck Depression Inventory (BDI) were recorded as descriptive
ariables.
.5. Statistical analyses
.5.1. Analgesic and anti-nociceptive effects
Continuous and ordinal variables that were roughly normally
istributed (NRS, PGIC, and CPM) or normally distributed after log-
ransformation (PPDT, PPTT, ESPT, and ERPT) were analyzed by
inear mixed models with treatment group, time point and their
nteraction as covariates. The models were adjusted for baseline
alues and treatment phase (oxycodone first vs. placebo first) in
rder to account for a possible learning effect. A carry-over effect
as excluded by design (wash-out period between the phases)
nd was not tested for. A random intercept was added for each
ubject (to account for intra-subject correlation) and a random
ntercept and slope for each subject in each treatment phase (to
ccount for repeated measures). Correlations between subsequent
easurements were modelled with a first order autoregressive cor-
elation structure. The treatment effect was calculated over all time
oints (joint p-value) and at each time point based on appropri-
te contrasts and is presented as mean difference or geometric
ean ratio (if data was log-transformed). Dichotomous variables
drug responders, dichotomized CPDT) were modelled by separate
ogistic generalized estimating equations (GEEs) at each time point
ith treatment group and phase as covariates and subject ID as
anel variable and the treatment effect is presented as odds ratio.
PDT and HPTT which were truncated at 50.5 ◦C were analyzed by
eparate mixed tobit regression models at each time point with
reatment group and phase as covariates and subject ID as panel
ariable. The treatment effect is presented as mean difference. Sam-
le size calculation was performed for the outcome of the main
roject, i.e. for the ability of baseline QST to predict the analgesic
ffect of the tested drug after 2 h. Detailed considerations can be
ound in the study protocol [7].
.5.2. Receiver-operating characteristics (ROC)
The ability of QST to reflect drug effect was assessed by receiver-
perating characteristic (ROC) analysis. For this purpose, only the
esults of the verum session were considered. Drug responder sta-
us in supine and sitting position 2 h after drug intake was used as
eference variable to classify patients into “positive” and “negative”
tate, respectively. The changes in QST after 2 h were expressed rel-
tive to baseline and used as classifying variables. The area under
he curve (AUC) and the 95% confidence intervals were calculated
y non-parametric ROC-analysis for the following QST parameters:
PDT, PPTT, ESPT, ERPT, HPDT at leg and arm, and time until cold
ressor pain reached NRS 7/10. Heat pain tolerance and cold pain
etection thresholds were not considered for ROC-analysis because
f the truncation at 50.5 ◦C and 0 ◦C, which was already reached at
aseline by a substantial number of patients. For the purpose of a
Published in final edited form as: Scand J Pain. 201ensitivity analysis, ROC AUCs were as well calculated for the situa-
ions when drug responders were defined as having ≥20% and ≥40%
ain reduction. All analyses were performed using STATA (STATA
orp, College station, Texas, USA).thresholds, Iwsec = time in ice water in seconds until cold pain reached 7 on a 0–10
numeric rating scale, HPDT and HPTT = heat pain detection and tolerance thresholds,
CPDT = cold pain detection thresholds.
3. Results
Fifty patients were enrolled and all of them completed both the
verum and the placebo session. There were 26 females and 24 males
with a mean age of 55 years (SD 15.2). Patient characteristics and
descriptive variables are shown in Table 1. Baseline values of QST
are shown in Table 2.
3.1. Low-back pain and QST
A significant analgesic effect compared to placebo occurred
after 30 min in the sitting and after 1 h in the supine position and
remained throughout the rest of the observation period. Supine
pain was 3.7 (95%-CI 3.4 to 4.1) at baseline and decreased to 1.5
(1.1 to 2.0) with oxycodone and to 3.0 (2.4 to 3.5) with placebo
after 2 h (p < 0.001). Sitting pain was 4.2 (3.9 to 4.5) at baseline
and decreased to 1.6 (1.2 to 2.1) with oxycodone and to 2.9 (2.3
to 3.4) with placebo after 2 h (p < 0.001). Time course of low-back
pain and proportion of responders are shown in Fig. 1. Significant
anti-nociceptive effects were observed for all QST except HPDT at
the leg after 120 min. CPM was at no time significantly different
between oxycodone and placebo. PGIC was between 3 (“minimal
improvement”) and 4 (“no change) in both arms with a significant
difference between treatments after 60 min only (see Table 3 for
detailed results of QST and treatment effects).
3.2. ROC-analysesFor pain in the supine position, there were 36 responders vs.
13 non-responders. One patient was unable to rate his pain in
the supine position (but had NRS > 3/10 in sitting position), ROC-
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ain intensity was measured in (a,c) supine or (b,d) sitting position. Values represe
he QST with the highest AUC were HPDT at the leg (AUC 0.65,
5%-CI 0.46 to 0.83), ESPT (0.64, 0.47 to 0.80) and PPDT (0.63, 0.48
o 0.79). For pain in the sitting position, there were 44 responders
s. 6 non-responders. Again, HPDT at the leg and ESPT showed the
ighest areas under the ROC-curve with 0.63 (0.35 to 0.90) for HPDT
nd 0.63 (0.42 to 0.83) for ESPT.
The sensitivity analysis with drug responders set as ≥20% pain
eduction showed almost uniformly smaller AUCs. On the other
and, when drug responders were defined as ≥40% pain reduction,
UCs did not or only minimally increase compared to ≥30% pain
eduction. Detailed results and 95%-CIs are displayed in Table 4,
OC curves for the supine and sitting position are displayed in
igs. 2 and 3.
.3. Sensitivity and specificity
As an example, sensitivity and specificity were calculated for
hose QST parameters with the highest AUC in supine position, i.e.
PDT, ESPT and HPDT at the leg. The chosen cutoffs were 1.11-fold
nd 1.2-fold increase from baseline for PPDT, 1.12-fold and 1.2-
old increase from baseline for ESPT and 1.006-fold and 1.02-fold
ncrease for HPDT. This choice was based on the experience of theing scale, NRS) and on (c,d) the proportion of responders (reduction in NRS ≥ 30%).
ans and 95% confidence intervals.
authors, i.e. when measuring PPDT or ESPT, a change in thresholds
by 10–20% is frequently observed, whereas for HPDT, changes of
0.5–1 ◦C (i.e. 1–2% increase) are far more realistic. Table 5 shows
the values of sensitivity and specificity for each QST parameter and
its respective cutoffs. Again, when the definition of responders was
changed to ≥20% or ≥40% pain reduction, sensitivity and specificity
were lower than with the definition of ≥30% pain reduction. In gen-
eral, sensitivity was modest for the selected QST parameters, the
most sensitive being a 12%-increase in ESPT yielding a 75% sensi-
tivity to identify a drug responder. However, specificity was 80–90%
for PPDT and HPDT, indicating that these tests are more useful to
rule out non-responders, rather than ruling in responders.
4. Discussion
4.1. Analgesic and anti-nociceptive effects in relation
This study showed that a single oral dose of oxycodone 15 mg
exerts a significant and immediate analgesic effect in chronic
low-back pain which significantly differs from placebo. The effect
occurred within 30 min in sitting position, but took slightly longer
when patients were supine. As a possible explanation, opioids may
Table 3
effect of oxycodone on quantitative sensory tests.
Time Oxycodone Placebo Geometric mean ratio (95% CI) p-value Joint p-value
mean (95% CI)*
ESPT (mA) 60 7.5 (6.6, 8.6) 7.1 (6.1, 8.2) 1.18 (1.08, 1.28) <0.001
120 8.3 (7.1, 9.6) 7.4 (6.3, 8.6) 1.21 (1.08, 1.36) 0.001 <0.001
ERPT (mA) 60 6.5 (5.7, 7.4) 5.8 (5.0, 6.7) 1.17 (1.08, 1.27) <0.001
120 7.0 (6.0, 8.1) 6.2 (5.3, 7.1) 1.17 (1.06, 1.29) 0.002 <0.001
PPDT (kPa) 60 322 (284, 364) 297 (271, 326) 1.08 (1.01, 1.16) 0.028
120 339 (300, 384) 308 (283, 335) 1.10 (1.02, 1.18) 0.011 0.025
PPTT (kPa) 60 483 (442, 528) 452 (417, 489) 1.10 (1.04, 1.15) <0.001
120 498 (456, 544) 462 (428, 500) 1.10 (1.05, 1.16) <0.001 <0.001
Iwsec (sec) 60 24.3 (19.9, 29.8) 21.1 (16.4, 27.1) 1.23 (1.11, 1.37) <0.001
120 21.8 (17.7, 26.9) 19.6 (15.4, 24.9) 1.16 (1.03, 1.30) 0.012 <0.001
Time Oxycodone Placebo Mean difference (95% CI) p-value Joint p-value
mean (95% CI)
HPDT (arm) 60 44.4 (43.1, 45.7) 44.3 (43.1, 45.6) 1.4 (0.5, 2.4) 0.002
(◦C) 120 44.3 (42.9, 45.6) 44.1 (42.8, 45.3) 1.5 (0.4, 2.5) 0.005
HPDT (leg) 60 47.2 (46.4, 48.0) 46.1 (45.1, 47.1) 1.6 (0.9, 2.2) <0.001
(◦C) 120 46.8 (45.8, 47.7) 46.4 (45.5, 47.4) 0.7 (-0.1, 1.5) 0.078
HPTT (arm) 60 49.0 (48.5, 49.6) 48.7 (48.0, 49.4) 0.8 (0.3, 1.2) 0.001
(◦C) 120 49.1 (48.5, 49.6) 48.8 (48.3, 49.4) 0.8 (0.4, 1.2) <0.001
HPTT (leg) 60 49.8 (49.5, 50.2) 49.4 (49.0, 49.8) 0.7 (0.3, 1.1) <0.001
(◦C) 120 49.9 (49.7, 50.2) 49.5 (49.1, 49.9) 0.7 (0.2, 1.1) 0.003
PGIC 30 3.7 (3.5, 3.9) 3.9 (3.7, 4.0) -0.18 (-0.46, 0.09) 0.193
60 3.4 (3.1, 3.7) 3.8 (3.6, 4.0) -0.42 (-0.75, -0.10) 0.011
90 3.4 (3.0, 3.8) 3.6 (3.4, 3.8) -0.22 (-0.61, 0.18) 0.278
120 3.2 (2.8, 3.6) 3.6 (3.4, 3.8) -0.42 (-0.89, 0.06) 0.084 0.089
CPM 60 0.69 (0.46, 0.92) 0.76 (0.51, 1.01) -0.06 (-0.36, 0.25) 0.722
120 0.55 (0.28, 0.81) 0.74 (0.50, 0.99) -0.18 (-0.53, 0.17) 0.304 0.590
Time Oxycodone Placebo Odds ratio (95% CI) p-value Joint p-value
proportion (95% CI)
CPDT (arm) 60 0.42 (0.28, 0.56) 0.28 (0.15, 0.41) 1.79 (1.07, 3.00) 0.027
At limit 120 0.46 (0.32, 0.60) 0.33 (0.19, 0.46) 1.74 (1.06, 2.84) 0.028
CPDT (leg) 60 0.56 (0.42, 0.70) 0.42 (0.28, 0.56) 1.80 (1.19, 2.71) 0.005
At limit 120 0.58 (0.44, 0.72) 0.44 (0.30, 0.58) 1.79 (1.12, 2.88) 0.016
Effect of oxycodone and placebo on experimental pain measures. ESPT/ERPT = electrical single/repeated stimulus pain threshold, PPDT/PPTT = pressure pain detec-
tion/tolerance threshold. HPDT/HPTT = heat pain detection/tolerance threshold, CPDT = cold pain detection threshold (dichotomized into “at limit”, i.e. reaching 0 ◦C without
pain, and “not at limit” i.e. pain before 0 ◦C was reached). Iwsec = time until cold pressor pain reached 7/10. CPM = conditioned pain modulation (expressed as proportional
change from baseline). PGIC = patients’ global impression of change scale (1–7 Likert-scale, 1 = very much improved, 7 = very much worse).
* calculated according to Cox’s direct method.
Table 4
areas under the receiver-operating characteristics curve.
N ROC AUC for x% pain reduction (95% CI)
a) x = 20% b) x = 30% c) x = 40%
Supine position
Ice time 49 0.54 (0.30, 0.77) 0.62 (0.44, 0.79) 0.62 (0.46, 0.79)
PPDT 49 0.54 (0.35, 0.73) 0.63 (0.48, 0.79) 0.52 (0.35, 0.69)
PPTT 49 0.38 (0.17, 0.60) 0.49 (0.30, 0.67) 0.51 (0.34, 0.67)
ESPT 49 0.54 (0.34, 0.74) 0.64 (0.47, 0.80) 0.61 (0.45, 0.77)
ERPT 49 0.52 (0.34, 0.70) 0.58 (0.43, 0.74) 0.59 (0.43, 0.75)
HPDT leg 49 0.51 (0.26, 0.76) 0.65 (0.46, 0.83) 0.55 (0.38, 0.71)
HPDT arm 47* 0.72 (0.53, 0.92) 0.63 (0.43, 0.83) 0.63 (0.47, 0.80)
Sitting position
Ice time 50 0.46 (0.21, 0.71) 0.48 (0.26, 0.70) 0.50 (0.30, 0.69)
PPDT 50 0.50 (0.22, 0.78) 0.51 (0.27, 0.75) 0.56 (0.37, 0.74)
PPTT 50 0.49 (0.25, 0.73) 0.53 (0.32, 0.74) 0.64 (0.47, 0.82)
ESPT 50 0.57 (0.35, 0.79) 0.63 (0.42, 0.83) 0.66 (0.49, 0.84)
ERPT 50 0.43 (0.18, 0.68) 0.46 (0.24, 0.68) 0.60 (0.44, 0.77)
HPDT leg 50 0.58 (0.26, 0.89) 0.63 (0.35, 0.90) 0.64 (0.46, 0.82)
HPDT arm 48* 0.56 (0.25, 0.86) 0.47 (0.18, 0.77) 0.61 (0.41, 0.80)
Non-parametric estimation for areas under the ROC-curve 2 hours after drug intake. Drug responders, i.e. positives, were defined as having a) ≥20%, b) ≥30% and c) ≥40% pain
reduction. Ice time = time until cold pressor pain reached 7/10 on the numeric rating scale. PPDT and PPTT = pressure pain detection and tolerance threshold, respectively.
ESPT and ERPT = electrical single and repeated stimulus pain threshold, respectively. HPDT = heat pain detection threshold.
* Two patients had no thermal pain testing due to thermode malfunction.
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PDT/PPTT = Pressure pain detection/tolerance threshold, ESPT/ERPT = electric singl
e particularly useful to suppress peak nociceptive signals, as may
esult from mechanical strain or injury, while they are less efficient
n blocking baseline nociceptive activity. The study simultaneously
onfirmed that oxycodone has anti-nociceptive effects on almost
ll sensory modalities, i.e. mechanical, electrical and thermal, and
hat they were affected in a manner similar to that observed in
ealthy volunteers [3–6].
Given the results from such studies, it might be tempting to infer
hat these anti-nociceptive effects translate into clinical analgesic
ffects in pain patients. However, not all QST reflected oxycodone
ffect on back pain to the same extent. For both supine and sittingn. Ice time = time until cold pain reaches 7 on the 0–10 numeric rating scale.
ated stimulus pain threshold, HPDT = heat pain detection threshold.
pain, HPDT at the leg and ESPT consistently showed the highest
areas under the ROC curve, with the maximal AUC of 0.65 observed
for HPDT at the leg in supine position. This indicates that HPDT
at the leg can correctly classify two randomly selected patients as
a responder and non-responder in only 65% of the cases. Notably,
the lower border of confidence intervals for all parameters is below
0.5, which means that they might not be significantly better than a
random classifier. Conversely, the upper border of confidence inter-
vals barely exceeded 0.8 (except for HPDT at the leg), which implies
that even under optimistic assumptions, QST could correctly clas-
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PDT/PPTT = Pressure pain detection/tolerance threshold, ESPT/ERPT = electric singl
ases. In the context of an approved drug like oxycodone, a 50–80%
ate of correct classification by QST is modest. However, in the con-
ext of a pre-clinical investigation of a novel substance, which is
ested first in volunteers before being used in pain patients, such
nformation might still be useful.
PPDT for pain in the supine position had an AUC of 0.63 (95%-
I 0.48 to 0.79). This parameter might therefore correctly classify
wo randomly selected patients in 63% of the cases. In the sitting
osition, however, PPDT was not as good a classifier. The most
robable explanation for the differences in AUC between sitting. Ice time = time until cold pain reaches 7 on the 0–10 numeric rating scale.
ated stimulus pain threshold, HPDT = heat pain detection threshold.
and supine position is the different proportion of responders and
non-responders. In supine position, the ratio of responders to non-
responders was 36:13, whereas in sitting position, it was 44:6. This
clearly limits the results of the ROC-analysis for the latter condition.
4.2. Sensitivity analysesThese results are contingent for a pain reduction ≥30% in
patients who responded to oxycodone. In order to investigate how
the ROC AUCs are influenced by this definition of responders, ROC
Table 5
sensitivity and specificity of selected cutoff values of sensory tests.
Cutoff Sensitivity Specificity LR+ LR-
20% pain reduction
PPDT 1.11 51% 67% 1.5 0.7
1.20 36% 83% 2.3 0.7
ESPT 1.12 73% 17% 0.9 1.6
1.20 56% 33% 0.8 1.3
HPDT leg 1.006 41% 67% 1.2 0.9
1.02 34% 83% 2.0 0.8
30% pain reduction
PPDT 1.11 58% 82% 3.2 0.5
1.20 44% 91% 4.9 0.6
ESPT 1.12 75% 27% 1.0 0.9
1.20 61% 55% 1.3 0.7
HPDT leg 1.006 47% 82% 2.6 0.6
1.02 39% 91% 4.3 0.7
40% pain reduction
PPDT 1.11 56% 67% 1.6 0.6
1.20 43% 80% 2.2 0.7
ESPT 1.12 75% 27% 1.0 0.9
1.20 62% 53% 1.3 0.7
HPDT leg 1.006 47% 73% 1.7 0.7
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s used for classifying. LR +/- = positive and negative likelihood ration, respectively. P
eg = heat pain detection threshold measured at the leg (L5-dermatome).
nalyses were carried out using ≥20% and ≥40% pain reduction as
lternative definitions of drug responders. In the former cases, the
UCs were consistently lower, whereas in the latter they did not
oticeably increase. A decrease in pain by ≥30% is often considered
linically meaningful, and the present results support the choice
f this cutoff from a mechanistic, QST-based point of view. Con-
erning the sensitivity and specificity of QST, it is difficult to define
cutoff. In general, drug responders showed a broad spectrum of
ncreases and decreases in QST parameters, whereas oxycodone
on-responders showed barely any increase in QST. This is reflected
y the rather modest sensitivity, but quite acceptable specificity of
he QST parameters in the present analyses. Of course, the exact val-
es of sensitivity and specificity depend on the cutoff one chooses,
nd the present results argue in favour of a cutoff that allows for a
igh specificity.
Among all recent studies investigating the effect of oxycodone,
nly one study combined the approach of using QST in chronic
ain patients [11]. They found significant anti-nociceptive effects,
specially on mechanical (i.e. skin pinch, muscle pressure) and
eat pain tests in patients with chronic pancreatitis. Unfortunately,
hey did not report about the clinical effects of oxycodone on pan-
reatitis pain, so that no conclusion can be drawn whether these
nti-nociceptive effects reflected clinical improvement as well.
.3. Strengths and limitations
The study is novel in the sense that it combines both clinical and
xperimental pain measures in a chronic pain population. As this
tudy was part of a larger investigation on low-back pain, sample
ize calculation was made for the primary aim of the project. There
as no a priori sample size calculation for the ROC analysis, which is
limitation to this study. The relatively wide confidence intervals
f the ROC AUCs might be an indication of lacking power. Yet, a
ample of 50 patients should allow for reasonable estimation of
ffect size and a larger sample would probably change the width of
he confidence intervals in the first line, rather than the effect size.
. ConclusionsThis study suggests that anti-nociceptive effects of oxycodone,
easured by QST, reflect clinical efficacy to varying degrees. This
hould be considered when interpreting QST results from studiesutoff values. Sensitivity and Specificity are highest again when ≥30% pain reduction
pressure pain detection threshold, PPTT = pressure pain tolerance threshold, HPDT
in pain-free volunteers. The QST parameters included in this study
show at best a modest association. Heat pain detection threshold,
single-stimulus electrical pain threshold and pressure pain detec-
tion threshold, may be more suitable classifiers, in particular to sort
out non-responders, rather than to identify potential responders to
the drug. Future pre-clinical human research may consider these
findings when investigating the analgesic effect of opioid agonists
by means of QST.
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